{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"114"}]}],"title":"TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"85"}]}],"title":"Drug-related AEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"title":"SAE"}],"denoms":[{"counts":[{"groupId":"OG000","value":"137"}],"units":"Participants"}],"description":"Safety analysis was based on the safety information from the laboratory evaluations, AEs, and SAEs.","groups":[{"description":"All subjects were males with advanced prostate carcinoma. They were injected twice with a depot formulation containing 50 mg of Leuprolide Mesylate. The first dose on day 0 the second dose on day 168 (six months apart). Subjects were followed until day 336.\n\nLeuprolide Mesylate: Subcutaneous injection of 50mg Leuprolide Mesylate","id":"OG000","title":"Leuprolide Mesylate 50mg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety population","reportingStatus":"POSTED","timeFrame":"336 days","title":"Number of Participants With Adverse Events (AEs)","type":"SECONDARY","unitOfMeasure":"Participants"}